Seladelpar

Seladelpar
Clinical data
Other names	MBX-8025; RWJ-800025
ATC code	None;
Legal status
Legal status	Investigational;
Identifiers
	IUPAC name 2-[4-[(2R)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid;
CAS Number	851528-79-5;
PubChem CID	11236126;
DrugBank	DB12390;
ChemSpider	9411171;
UNII	7C00L34NB9;
KEGG	D11256;
ChEMBL	ChEMBL230158;
Chemical and physical data
Formula	C21H23F3O5S
Molar mass	444.47 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CCO[C@H](COC1=CC=C(C=C1)C(F)(F)F)CSC2=CC(=C(C=C2)OCC(=O)O)C;
	InChI InChI=1S/C21H23F3O5S/c1-3-27-17(11-28-16-6-4-15(5-7-16)21(22,23)24)13-30-18-8-9-19(14(2)10-18)29-12-20(25)26/h4-10,17H,3,11-13H2,1-2H3,(H,25,26)/t17-/m1/s1; Key:JWHYSEDOYMYMNM-QGZVFWFLSA-N;

Seladelpar (INN, USAN; developmental code names MBX-8025, RWJ-800025) is a PPARδ receptor agonist that is being investigated for drug use by Metabolex.^[1]^[2]^[3] According to a press release they are examining its potential use for the treatment of dyslipidemia, metabolic syndrome, type 2 diabetes, and non-alcoholic steatohepatitis (NASH). The compound was licensed from Janssen Pharmaceutica NV.^[4]

References[]

^ "Seladelpar - CymaBay Therapeutics - AdisInsight".
^ Billin, A. N. (2008). "PPAR-β/δ agonists for Type 2 diabetes and dyslipidemia: An adopted orphan still looking for a home". Expert Opinion on Investigational Drugs. 17 (10): 1465–1471. doi:10.1517/13543784.17.10.1465. PMID 18808307. S2CID 86564263.
^ Bays HE, Schwartz S, Littlejohn T, Kerzner B, Krauss RM, Karpf DB, Choi YJ, Wang X, Naim S, Roberts BK (September 2011). "MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin". J. Clin. Endocrinol. Metab. 96 (9): 2889–97. doi:10.1210/jc.2011-1061. PMID 21752880.
^ "Targeting Mixed Dyslipidemia and Metabolic Syndrome". Archived from the original on 2006-10-17.

External links[]

Seladelpar - AdisInsight

This drug article relating to the gastrointestinal system is a stub. You can help Wikipedia by .

[AdisInsight-1] "Seladelpar - CymaBay Therapeutics - AdisInsight".

[pmid18808307-2] Billin, A. N. (2008). "PPAR-β/δ agonists for Type 2 diabetes and dyslipidemia: An adopted orphan still looking for a home". Expert Opinion on Investigational Drugs. 17 (10): 1465–1471. doi:10.1517/13543784.17.10.1465. PMID 18808307. S2CID 86564263.

[pmid21752880-3] Bays HE, Schwartz S, Littlejohn T, Kerzner B, Krauss RM, Karpf DB, Choi YJ, Wang X, Naim S, Roberts BK (September 2011). "MBX-8025, a novel peroxisome proliferator receptor-delta agonist: lipid and other metabolic effects in dyslipidemic overweight patients treated with and without atorvastatin". J. Clin. Endocrinol. Metab. 96 (9): 2889–97. doi:10.1210/jc.2011-1061. PMID 21752880.

[Metabolex2006-4] "Targeting Mixed Dyslipidemia and Metabolic Syndrome". Archived from the original on 2006-10-17.

[1]

[2]

[3]

[4]

v t PPAR modulators
PPARα	Agonists: 15-HETE Aleglitazar Aluminium clofibrate Arachidonic acid Bezafibrate Clofibrate Daidzein DHEA (prasterone) (in rodents) Elafibranor Etomoxir Fenofibrate Genistein Gemfibrozil Leukotriene B₄ Lobeglitazone Muraglitazar Oleylethanolamide Palmitoylethanolamide Pemafibrate Perfluorononanoic acid Perfluorooctanoic acid Pioglitazone Saroglitazar Sodelglitazar Tesaglitazar Tetradecylthioacetic acid Troglitazone Antagonists: MK-886
PPARδ	Agonists: 15-HETE Arachidonic acid Bezafibrate Daidzein Elafibranor Genistein GW-0742 GW-501516 Seladelpar Sodelglitazar Tetradecylthioacetic acid Antagonists:
PPARγ	Agonists: 15-Deoxy-Δ^12,14-prostaglandin J₂ 15-HETE Aleglitazar Arachidonic acid Berberine Bezafibrate Cannabidiol Ciglitazone Daidzein Darglitazone Englitazone Etalocib Farglitazar Genistein Ibuprofen Indeglitazar Lobeglitazone Muraglitazar (muroglitazar) Netoglitazone Perfluorononanoic acid Pioglitazone Rivoglitazone Rosiglitazone Saroglitazar Sodelglitazar Telmisartan Tesaglitazar Troglitazone SPPARMs: BADGE EPI-001 Antagonists: Unknown:
Non-selective	Agonists: Ciprofibrate Clinofibrate Clofibride Englitazone Etofibrate Farglitazar Netoglitazone Ronifibrate Rivoglitazone Simfibrate
See also Receptor/signaling modulators

Seladelpar

See also[]

References[]

External links[]